Polymorphisms in Plasmodium Falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. Falciparum Malaria After Artemether-lumefantrine and Artesunate-amodiaquine

Adequate clinical and parasitologic cure by artemisinin combination therapies relies on the artemisinin component and the partner drug. Polymorphisms in the Plasmodium falciparum chloroquine resistance transporter (pfcrt) and P. falciparum multidrug resistance 1 (pfmdr1) genes are associated with decreased sensitivity to amodiaquine and lumefantrine, but effects of these polymorphisms on therapeutic responses to artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) have not been clearly defined. Individual patient data from 31 clinical trials were harmonized and pooled by using standardized methods from the WorldWide Antimalarial Resistance Network. Data for more than 7,000 patients were analyzed to assess relationships between parasite polymorphisms in pfcrt and pfmdr1 and clinically relevant outcomes after treatment with AL or ASAQ. Presence of the pfmdr1 gene N86 (adjusted hazards ratio = 4.74, 95% confidence interval = 2.29 - 9.78, P < 0.001) and increased pfmdr1 copy number (adjusted hazards ratio = 6.52, 95% confidence interval = 2.36-17.97, P < 0.001 : were significant independent risk factors for recrudescence in patients treated with AL. AL and ASAQ exerted opposing selective effects on single-nucleotide polymorphisms in pfcrt and pfmdr1. Monitoring selection and responding to emerging signs of drug resistance are critical tools for preserving efficacy of artemisinin combination therapies; determination of the prevalence of at least pfcrt K76T and pfmdr1 N86Y should now be routine.

Citing Articles

Monitoring molecular markers associated with antimalarial drug resistance in south-east Senegal from 2021 to 2023.

Wade A, Sene S, Caspar E, Diallo F, Platon L, Thiebaut L J Antimicrob Chemother. 2025; 80(3):828-839.

PMID: 39846779 PMC: 11879165. DOI: 10.1093/jac/dkaf006.

Stereospecific Resistance to N2-Acyl Tetrahydro-β-carboline Antimalarials Is Mediated by a PfMDR1 Mutation That Confers Collateral Drug Sensitivity.

Bremers E, Butler J, Do Amaral L, Merino E, Almolhim H, Zhou B ACS Infect Dis. 2025; 11(2):529-542.

PMID: 39808111 PMC: 11828674. DOI: 10.1021/acsinfecdis.4c01001.

Polymorphisms in the Pfcrt, Pfmdr1, and Pfk13 genes of Plasmodium falciparum isolates from southern Brazzaville, Republic of Congo.

Baina M, Djontu J, Mbama Ntabi J, Mfoutou Mapanguy C, Lissom A, Vouvoungui C Sci Rep. 2024; 14(1):27988.

PMID: 39543235 PMC: 11564878. DOI: 10.1038/s41598-024-78670-2.

A novel 4-aminoquinoline chemotype with multistage antimalarial activity and lack of cross-resistance with PfCRT and PfMDR1 mutants.

Ferreira L, Cassiano G, Alvarez L, Okombo J, Calit J, Fontinha D PLoS Pathog. 2024; 20(10):e1012627.

PMID: 39471233 PMC: 11521309. DOI: 10.1371/journal.ppat.1012627.

Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in mainland Tanzania, 2019.

Ngasala B, Chiduo M, Mmbando B, Francis F, Bushukatale S, Makene T Malar J. 2024; 23(1):101.

PMID: 38594679 PMC: 11005286. DOI: 10.1186/s12936-024-04931-0.

References

Mu J, Ferdig M, Feng X, Joy D, Duan J, Furuya T . Multiple transporters associated with malaria parasite responses to chloroquine and quinine. Mol Microbiol. 2003; 49(4):977-89. DOI: 10.1046/j.1365-2958.2003.03627.x. View

Fidock D, Nomura T, Talley A, Cooper R, Dzekunov S, Ferdig M . Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000; 6(4):861-71. PMC: 2944663. DOI: 10.1016/s1097-2765(05)00077-8. View

Duraisingh M, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst D . The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol Biochem Parasitol. 2000; 108(1):13-23. DOI: 10.1016/s0166-6851(00)00201-2. View

Happi C, Gbotosho G, Folarin O, Bolaji O, Sowunmi A, Kyle D . Association between mutations in Plasmodium falciparum chloroquine resistance transporter and P. falciparum multidrug resistance 1 genes and in vivo amodiaquine resistance in P. falciparum malaria-infected children in Nigeria. Am J Trop Med Hyg. 2006; 75(1):155-61. View

Price R, Uhlemann A, Brockman A, McGready R, Ashley E, Phaipun L . Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet. 2004; 364(9432):438-447. PMC: 4337987. DOI: 10.1016/S0140-6736(04)16767-6. View

Folarin O, Bustamante C, Gbotosho G, Sowunmi A, Zalis M, Oduola A . In vitro amodiaquine resistance and its association with mutations in pfcrt and pfmdr1 genes of Plasmodium falciparum isolates from Nigeria. Acta Trop. 2011; 120(3):224-30. PMC: 3214618. DOI: 10.1016/j.actatropica.2011.08.013. View

Reed M, Saliba K, Caruana S, Kirk K, Cowman A . Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature. 2000; 403(6772):906-9. DOI: 10.1038/35002615. View

Choudhury J . Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data. Stat Med. 2002; 21(8):1129-44. DOI: 10.1002/sim.1070. View

Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, Bjorkman A . In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis. 2005; 191(6):1014-7. DOI: 10.1086/427997. View

10.

Dokomajilar C, Nsobya S, Greenhouse B, Rosenthal P, Dorsey G . Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother. 2006; 50(5):1893-5. PMC: 1472234. DOI: 10.1128/AAC.50.5.1893-1895.2006. View

11.

Bethell D, Teja-Isavadharm P, Cao X, Pham T, Ta T, Tran T . Pharmacokinetics of oral artesunate in children with moderately severe Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg. 1997; 91(2):195-8. DOI: 10.1016/s0035-9203(97)90222-4. View

12.

Gadalla N, Adam I, Elzaki S, Bashir S, Mukhtar I, Oguike M . Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether-lumefantrine. Antimicrob Agents Chemother. 2011; 55(11):5408-11. PMC: 3195064. DOI: 10.1128/AAC.05102-11. View

13.

Thwing J, Odero C, Odhiambo F, Otieno K, Kariuki S, Ord R . In-vivo efficacy of amodiaquine-artesunate in children with uncomplicated Plasmodium falciparum malaria in western Kenya. Trop Med Int Health. 2009; 14(3):294-300. PMC: 5799880. DOI: 10.1111/j.1365-3156.2009.02222.x. View

14.

Danquah I, Coulibaly B, Meissner P, Petruschke I, Muller O, Mockenhaupt F . Selection of pfmdr1 and pfcrt alleles in amodiaquine treatment failure in north-western Burkina Faso. Acta Trop. 2010; 114(1):63-6. DOI: 10.1016/j.actatropica.2009.12.008. View

15.

Abuaku B, Duah N, Quaye L, Quashie N, Koram K . Therapeutic efficacy of artemether-lumefantrine combination in the treatment of uncomplicated malaria among children under five years of age in three ecological zones in Ghana. Malar J. 2012; 11:388. PMC: 3519607. DOI: 10.1186/1475-2875-11-388. View

16.

Siribie M, Diarra A, Tiono A, Soulama I, Sirima S . [Efficacy of artemether-lumefantrine in the treatment of uncomplicated malaria in children living in a rural area of Burkina Faso in 2009]. Bull Soc Pathol Exot. 2012; 105(3):202-7. DOI: 10.1007/s13149-012-0209-6. View

17.

Mukhtar E, Gadalla N, El-Zaki S, Mukhtar I, Mansour F, Babiker A . A comparative study on the efficacy of artesunate plus sulphadoxine/pyrimethamine versus artemether-lumefantrine in eastern Sudan. Malar J. 2007; 6:92. PMC: 1940006. DOI: 10.1186/1475-2875-6-92. View

18.

Mutabingwa T, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C . Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet. 2005; 365(9469):1474-80. DOI: 10.1016/S0140-6736(05)66417-3. View

19.

Tinto H, Guekoun L, Zongo I, Guiguemde R, DAlessandro U, Ouedraogo J . Chloroquine-resistance molecular markers (Pfcrt T76 and Pfmdr-1 Y86) and amodiaquine resistance in Burkina Faso. Trop Med Int Health. 2008; 13(2):238-40. DOI: 10.1111/j.1365-3156.2007.01995.x. View

20.

Holmgren G, Hamrin J, Svard J, Martensson A, Gil J, Bjorkman A . Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa. Infect Genet Evol. 2007; 7(5):562-9. DOI: 10.1016/j.meegid.2007.03.005. View